Business
Moderna and Samsung Biologics Announce Agreement for Fill-Finish Manufacturing of Moderna's COVID-19 Vaccine
The agreement will further enable global supply of mRNA-1273, Moderna's COVID-19 vaccine with Samsung Biologics' fill and finish manufacturing service
About this update from Moderna, Inc.
[{"type":"text","content":"The agreement will further enable global supply of mRNA-1273, Moderna's COVID-19 vaccine with Samsung Biologics' fill and finish manufacturing service\n\n\nCAMBRIDGE, Mass. and INCHEON, South Korea, May 22, 2021 /PRNewswire/ -- Moderna (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Samsung Biologics (KRX: 207940.KS), a leading global CDMO providing a fully integrated end-to-end contract development and manufacturing service, today announced a Manufacturing Services and Supply Agreement in which Samsung Biologics will provide large scale, commercial fill-finish manufacturing for mRNA-1273, Moderna's COVID-19 vaccine. \n\n \n \n \n \n \n \n\n \nUpon execution of the deal, technology transfer will commence immediately at Samsung Biologics' facilities in Incheon, South Korea, utilizing a state-of-the-art production line equipped for aseptic fill-finish, labeling, and packaging services to support the production of hundreds of millions of doses of Moderna's COVID-19 vaccine intended for the supply of markets outside of the U.S. starting in the third quarter of 2021.\n\"This vaccine is paramount to people around the world in the fight against the COVID-19 pandemic, and we truly appreciate our client Moderna for entrusting and choosing to partner with Samsung Biologics for the fill and finish of this important vaccine,\" said John Rim, CEO of Samsung Biologics. \"Due to the high level of urgency in supplying the vaccine to the global population, we have set immediate action plans and schedule to make mRNA-1273 available for commercial distribution in the early second half of 2021.\"\n\"We are pleased to partner with Samsung Biologics for this fill and finish manufacturing, which will help us continue to scale up our manufacturing capacity outside of the U.S.,\" said Juan Andres, Moderna's Chief Technical Operations and Quality Officer. \"We and our manufacturing partners remain committed to defeating the COVID-19 pandemic.\"\nAbout ModernaIn 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formul...